Burger, JA, Robak, T, Demirkan, F, Bairey, O, Moreno, C, Simpson, D, Munir, T, Stevens, DA, Dai, S, Cheung, LWK, Kwei, K, Lal, I, Hsu, EM, Kipps, TJ, Tedeschi, A. Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studies. LEUKEMIA & LYMPHOMA. 2022; 63(6)DOI:10.1080/10428194.2021.2020779. PMID:35014928. IF:2.600(Q3/7D).

Halwani, AS, Panizo, C, Isufi, I, Herrera, AF, Okada, CY, Cull, EH, Kis, B, Chaves, JM, Bartlett, NL, Ai, WY, De La Cruz-Merino, L, Bryan, LJ, Houot, R, Linton, K, Briones, J, Chau, I, von Keudell, GR, Lu, HL, Yakovich, A, Chen, M, Ter Meulen, JH, Yurasov, S, Hsu, FJ, Flowers, CR. Phase 1/2 study of intratumoral G100 (TLR4 agonist) with or without pembrolizumab in follicular lymphoma. LEUKEMIA & LYMPHOMA. 2022; 63(4)DOI:10.1080/10428194.2021.2010057. PMID:34865586. IF:2.600(Q3/7D).

Hernandez-Boluda, JC, Pereira, A, Zinger, N, Gras, L, Martino, R, Paneesha, S, Finke, J, Chinea, A, Rambaldi, A, Robin, M, Saccardi, R, Natale, A, Snowden, JA, Tsirigotis, P, Vallejo, C, Wulf, G, Xicoy, B, Russo, D, Maertens, J, Daguindau, E, Lenhoff, S, Hayden, P, Czerw, T, McLornan, DP, Yakoub-Agha, I. Allogeneic hematopoietic cell transplantation in patients with myeloid/lymphoid neoplasm with FGFR1-rearrangement: a study of the Chronic Malignancies Working Party of EBMT. BONE MARROW TRANSPLANTATION. 2022; 57(3)DOI:10.1038/s41409-021-01553-x. PMID:35066569. IF:4.800(Q1/2D).

Pinana, JL, Vazquez, L, Martino, R, de la Camara, R, Sureda, A, Rodriguez-Veiga, R, Garrido, A, Sierra, J, Ribera, JM, Torrent, A, Mateos, MV, de la Rubia, J, Tormo, M, Diez-Campelo, M, Garcia-Gutierrez, V, Alvarez-Larran, A, Sancho, JM, MartinGarcia-Sancho, A, Yanez, L, Simon, JAP, Barba, P, Abrisqueta, P, Alvarez-Twose, I, Bonanad, S, Lecumberri, R, Ruiz-Camps, I, Navarro, D, Hernandez-Rivas, JA, Cedillo, A, Garcia-Sanz, R, Bosch, F. Spanish Society of Hematology and Hemotherapy expert consensus opinion for SARS-CoV-2 vaccination in onco-hematological patients. LEUKEMIA & LYMPHOMA. 2022; 63(3)DOI:10.1080/10428194.2021.1992619. PMID:34668835. IF:2.600(Q3/7D).

Martino, R, Garcia-Cadenas, I, Esquirol, A. Daratumumab may be the most effective treatment for post-engraftment pure red cell aplasia due to persistent anti-donor isohemagglutinins after major ABO-mismatched allogeneic transplantation. BONE MARROW TRANSPLANTATION. 2022; 57(2)DOI:10.1038/s41409-021-01507-3. PMID:34711914. IF:4.800(Q1/2D).

Dlouhy, I, Karube, K, Enjuanes, A, Salaverria, I, Nadeu, F, Ramis-Zaldivar, JE, Valero, JG, Rivas-Delgado, A, Magnano, L, Martin-Garcia, D, Perez-Galan, P, Clot, G, Rovira, J, Jares, P, Balague, O, Gine, E, Mozas, P, Briones, J, Sancho, JM, Salar, A, Mercadal, S, Alcoceba, M, Valera, A, Campo, E, Lopez-Guillermo, A. Revised International Prognostic Index and genetic alterations are associated with early failure to R-CHOP in patients with diffuse large B-cell lymphoma. BRITISH JOURNAL OF HAEMATOLOGY. 2022; 196(3)DOI:10.1111/bjh.17858. PMID:34632572. IF:6.500(Q1/3D).

Ribera, J, Granada, I, Morgades, M, Gonzalez, T, Ciudad, J, Such, E, Calasanz, MJ, Mercadal, S, Coll, R, Gonzalez-Campos, J, Tormo, M, Garcia-Cadenas, I, Gil, C, Cervera, M, Barba, P, Costa, D, Ayala, R, Bermudez, A, Orfao, A, Ribera, JM. Prognostic heterogeneity of adult B-cell precursor acute lymphoblastic leukaemia patients with t(1;19)(q23;p13)/ TCF3-PBX1 treated with measurable residual disease-oriented protocols. BRITISH JOURNAL OF HAEMATOLOGY. 2022; 196(3)DOI:10.1111/bjh.17844. PMID:34549416. IF:6.500(Q1/3D).

Allan, JN, Shanafelt, T, Wiestner, A, Moreno, C, O'Brien, SM, Li, JL, Krigsfeld, G, Dean, JP, Ahn, IE. Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials. BRITISH JOURNAL OF HAEMATOLOGY. 2022; 196(4)DOI:10.1111/bjh.17984. PMID:34865212. IF:6.500(Q1/3D).